• Explore /
  • Poster
  • / Profiling circulating tumor (ct)DNA mutations after panitumumab treatment in patients with refractory metastatic colorectal cancer (mCRC) from the phase III ASPECCT study.

Profiling circulating tumor (ct)DNA mutations after panitumumab treatment in patients with refractory metastatic colorectal cancer (mCRC) from the phase III ASPECCT study.

Abstract Poster

Authors

null

Michael Boedigheimer

Amgen Inc., Thousand Oaks, CA

Michael Boedigheimer , Agnes Ang , Timothy Jay Price , Marc Peeters , Tae Won Kim , Peter Gibbs , Anne L. Thomas , Kristina Hool , Bruce A. Bach

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Epidemiology/Outcomes

Clinical Trial Registration Number

NCT01001377

Citation

J Clin Oncol 35, 2017 (suppl; abstr 3523)

DOI

10.1200/JCO.2017.35.15_suppl.3523

Abstract #

3523

Poster Bd #

146

Abstract Disclosures

Similar Posters

Poster

2018 ASCO Annual Meeting

Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.

Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.

First Author: Razelle Kurzrock

First Author: Gemma Bruera

First Author: Daniela Adua

First Author: Camila Bragança Xavier